Compare ARK Genomic Revolution ETF (ARKG) vs Synchrony Financial (SYF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Synchrony Financial — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while Synchrony Financial trades at $72.44 (market cap $24.37B). The key difference: Synchrony Financial pays a 1.66% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Synchrony Financial nearer its low. Which is the better fit depends on your goals.
| ARKG | SYF | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $43.57 | $88.47 |
52-Week Low | $23.09 | $63.78 |
Market Cap | — | $24.37B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Synchrony Financial (SYF) trades at $72.44, up 1.22% with strong fundamental metrics including a low P/E of 7.5 and robust ROE of 22.98%. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 results expected July 21. Technical indicators show bearish momentum despite neutral oscillators, with key support at $69 and resistance at $73. Recent corporate developments include executive leadership changes and expansion of CareCredit partnerships.
SYF presents a compelling value opportunity with attractive valuation multiples and consistent earnings performance. The stock offers 19% upside to consensus price target of $86, supported by strong analyst sentiment (62.5% buy ratings). Key risks include economic sensitivity to consumer credit and inflationary pressures. The upcoming Q2 earnings report will be crucial for confirming the company's growth trajectory amid current market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
